BioXcel Therapeutics (BTAI.Q) Resumen de Acciones
BioXcel Therapeutics, Inc. junto con su filial OnkosXcel Therapeutics LLC, opera como empresa biofarmacéutica que utiliza enfoques de inteligencia artificial para desarrollar medicamentos en neurociencia e inmuno-oncología en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 2/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 0/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
+ 3 riesgos adicionales
BTAI.Q Community Fair Values
Create NarrativeSee what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de BioXcel Therapeutics, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$0.051 |
| Máximo en las últimas 52 semanas | US$3.41 |
| Mínimo de 52 semanas | US$0.019 |
| Beta | 0.19 |
| Cambio en 1 mes | -95.19% |
| Variación en 3 meses | -95.53% |
| Cambio de 1 año | -98.36% |
| Variación en 3 años | -99.90% |
| Variación en 5 años | -99.90% |
| Variación desde la OPV | -99.90% |
Noticias y actualizaciones recientes
Recent updates
BTAI: At Home Agitation Data And Index Additions Will Drive Upside
Analysts have lifted their fair value estimate for BioXcel Therapeutics from about $14 to roughly $18.33 per share, citing updated assumptions on revenue growth, profit margins and future P/E levels that feed into a higher price target. What’s in the News for BioXcel Therapeutics BioXcel Therapeutics was added to the Russell 3000E Growth Benchmark Index, according to index constituent update data.BTAI: At Home Agitation Opportunity Will Drive Future Upside Potential
Analysts have reiterated their $14.00 price target on BioXcel Therapeutics, reflecting only slight adjustments in assumptions around discount rate, profit margin and future P/E, and indicating that their overall valuation view on the stock remains largely unchanged. What’s in the News for BioXcel Therapeutics BioXcel Therapeutics reported new positive exploratory efficacy data from the Phase 3 SERENITY At-Home trial of BXCL501 for agitation in bipolar disorders or schizophrenia in the at-home setting, showing reduced agitation versus placebo across mild, moderate, and severe baseline symptom levels, with benefit maintained over repeated dosing, source: 2026 American Society of Clinical Psychopharmacology Annual Meeting.BTAI: At Home Agitation Franchise Will Unlock Future Upside Potential
Analysts have lifted their price target on BioXcel Therapeutics stock to $17, up from $14, citing what they view as a differentiated at-home agitation franchise, expanding BXCL501 neuropsychiatry options, and a wide gap between the current enterprise value and the company's risk adjusted cash flow potential. What's in the News BioXcel Therapeutics reported new positive data from the Phase 3 SERENITY At-Home trial of BXCL501 in agitation tied to bipolar disorders or schizophrenia in the at home setting, with exploratory analyses showing reduced agitation versus placebo across mild, moderate, and severe baseline symptoms, and benefit observed with repeated dosing.BTAI: At Home Agitation Opportunity Will Drive Future Upside Despite Dilution
Analysts have reset BioXcel Therapeutics' blended price target closer to $6, reflecting recent equity dilution while still pointing to what they view as attractive upside from the company's differentiated at home agitation franchise and expanding BXCL501 neuropsychiatry opportunities. Analyst Commentary Recent Street commentary on BioXcel Therapeutics centers on how to balance dilution driven pressure on the share price with what analysts see as meaningful potential around the BXCL501 franchise and the broader neuropsychiatry pipeline.BTAI: At Home Agitation Franchise Will Drive Future Repricing Despite Dilution
Narrative Update The analyst fair value estimate for BioXcel Therapeutics has been adjusted slightly to $14.00 from $14.25, as analysts weigh the recent equity dilution against ongoing views that BXCL501's at-home agitation use and broader neuropsychiatry potential support a higher upside than current trading levels suggest. Analyst Commentary Recent Street research highlights a split view on BioXcel Therapeutics, with some analysts focused on the long-term potential of BXCL501 and others more focused on balance sheet pressure from equity issuance.BTAI: At Home Agitation Expansion Will Drive Repricing Despite Dilution Concerns
Analysts now set an updated $14.25 price target for BioXcel Therapeutics, refining their outlook as they weigh enthusiasm around the at-home agitation franchise and expanding BXCL501 options against recent and expected equity dilution. Analyst Commentary Recent Street research reflects a split view on BioXcel Therapeutics, with some analysts emphasizing upside tied to the at-home agitation portfolio and others focusing more on the impact of equity dilution on upside potential.BTAI: At Home Agitation sNDA Will Drive Repricing Despite Equity Dilution Concerns
Analysts have trimmed their fair value estimate for BioXcel Therapeutics from $15.25 to $14.25, reflecting a lower price target after recent Street research highlighted equity dilution as a key concern. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential even after the price target adjustment to US$6, suggesting they believe current valuation already reflects a good portion of the equity dilution risk.BTAI: At Home Agitation sNDA And Planning Will Drive Repricing Potential
Analysts kept their $15.25 price target for BioXcel Therapeutics unchanged, citing relatively steady modeled fair value, a similar discount rate and revenue outlook, and only modest tweaks to profit margin and future P/E assumptions. What's in the News Completed an updated market opportunity assessment for IGALMI for acute agitation in bipolar disorder or schizophrenia in the at home setting, using insights from the SERENITY At Home study to guide launch planning.BTAI: At Home Agitation Use Expansion Will Drive Repricing Potential
Analysts now see fair value for BioXcel Therapeutics at US$15.25, down from US$16.75. This reflects updated assumptions for growth, profitability and a higher future P/E multiple in their models.BTAI: At Home Agitation Approval Effort Will Drive Repricing Potential
Analysts have revised their price target for BioXcel Therapeutics to US$16.75, with the change largely tied to updated assumptions for the discount rate, profit margin outlook, and a slightly lower future P/E multiple. What's in the News Submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for IGALMI for at home treatment of agitation tied to bipolar disorders or schizophrenia, aiming to expand use beyond healthcare provider supervised settings where there are currently no FDA approved options (Key Developments).BTAI: At Home Agitation sNDA And Safety Data Will Drive Repricing
Analysts have modestly reset their price target for BioXcel Therapeutics to US$16.75. This reflects updated assumptions around discount rate, profit margin, and future P/E that keep their fair value view broadly unchanged.BTAI: At Home Agitation Approval Pathway Will Drive Bullish Repricing
Narrative Update on BioXcel Therapeutics Analysts have modestly lifted their price target on BioXcel Therapeutics, citing a reaffirmed fair value estimate near $16.75 per share, supported by stable long term growth and profitability assumptions, despite a slightly higher discount rate and modestly richer projected valuation multiples. What's in the News Shareholders are scheduled to vote at the December 12, 2025 AGM on an amendment to the certificate of incorporation that would enable a reverse stock split, which may reflect efforts to maintain listing compliance and improve share price optics (company filing).BTAI: Phase 3 At Home Agitation Data Will Drive Bullish Repricing
Analysts have raised their price target on BioXcel Therapeutics to $4 from $2, citing stronger long term risk adjusted sales potential for BXCL501 supported by positive Phase 3 SERENITY At Home data, while still flagging financing uncertainty. Analyst Commentary Analysts updating their models following the SERENITY At Home readout are highlighting both improved long term revenue potential and persistent execution risks that temper the valuation upside.BTAI: Strong Phase 3 Study Results Will Drive Further Market Momentum
Analysts have lowered their fair value estimate for BioXcel Therapeutics from $23.75 to $16.75 per share, citing improved long-term revenue projections and profit margins. This outlook is balanced by ongoing uncertainties related to the company’s financing strategy.BTAI: Upcoming Regulatory Milestones Will Drive Momentum Following Key Phase 3 Success
Analysts have increased their fair value price target for BioXcel Therapeutics from $19 to $23.75, citing improved revenue growth expectations, a higher profit margin forecast, and optimism following positive BXCL501 study results as well as expanded indications. Analyst Commentary Recent analyst updates reflect a mix of optimism and ongoing caution surrounding BioXcel Therapeutics following positive developments for BXCL501 and improving financial projections.
BXCL501 And SERENITY Trials Will Unlock New Treatment Horizons
Advancing Phase III trials and successful SERENITY outcomes could expand market access and boost revenue through FDA approvals and new partnerships.Rentabilidad de los accionistas
| BTAI.Q | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -31.0% | -5.9% | -2.2% |
| 1Y | -98.4% | 34.6% | 13.1% |
Rentabilidad vs. Industria: Los resultados de BTAI.Q fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 34.6% el año pasado.
Rentabilidad vs. Mercado: BTAI.Q obtuvo unos resultados inferiores a los del mercado US, que fueron del 13.1% el año pasado.
Volatilidad de los precios
| BTAI.Q volatility | |
|---|---|
| BTAI.Q Average Weekly Movement | 31.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Precio estable de las acciones: El precio de las acciones de BTAI.Q ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de BTAI.Q ha aumentado de 19% a 31% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2017 | 29 | Vimal Mehta | www.bioxceltherapeutics.com |
BioXcel Therapeutics, Inc., junto con su filial, OnkosXcel Therapeutics LLC, opera como una empresa biofarmacéutica que utiliza técnicas de inteligencia artificial para desarrollar medicamentos en los campos de la neurociencia y la inmuno-oncología en Estados Unidos. La empresa comercializa IGALMI, una película sublingual para el tratamiento agudo de la agitación asociada a la esquizofrenia o al trastorno bipolar de tipo I o II en adultos. También desarrolla su candidato en el ámbito de la neurociencia, el BXCL501, una formulación en película sublingual de dexmedetomidina, en fase de investigación, de desarrollo propio y de disolución oral, que se encuentra en ensayo de fase III para el tratamiento de la agitación asociada a los trastornos bipolares, la esquizofrenia, y la enfermedad de Alzheimer, así como el trastorno por consumo de opiáceos, el trastorno por consumo de alcohol con trastorno de estrés postraumático comórbido y el trastorno de estrés agudo; y su candidato en inmuno-oncología, BXCL701, un activador oral del sistema inmunitario innato en fase de investigación que ha completado el ensayo de fase 1b/2a para el tratamiento de formas agresivas de cáncer de próstata, cáncer de páncreas y otros tumores sólidos y líquidos.
Resumen de fundamentos de BioXcel Therapeutics, Inc.
| Estadísticas fundamentales de BTAI.Q | |
|---|---|
| Capitalización bursátil | US$1.57m |
| Beneficios(TTM) | -US$70.86m |
| Ingresos (TTM) | US$742.00k |
¿Está BTAI.Q sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de BTAI.Q | |
|---|---|
| Ingresos | US$742.00k |
| Coste de los ingresos | US$348.00k |
| Beneficio bruto | US$394.00k |
| Otros gastos | US$71.25m |
| Beneficios | -US$70.86m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.26 |
| Margen bruto | 53.10% |
| Margen de beneficio neto | -9,549.87% |
| Ratio deuda/patrimonio | -90.5% |
¿Cómo se ha desempeñado BTAI.Q a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/11 00:33 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
BioXcel Therapeutics, Inc. está cubierta por 9 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Anita Dushyanth | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |